Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.
Abstract
This study compared intramuscular and subcutaneous administration of two doses of measles-mumps-rubella-varicella (MMRV) combination vaccine (Priorix-Tetra, GlaxoSmithKline Biologicals) in children.
Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously.
Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes.
Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration.
Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings.
In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.
Full Text
Subjects
Similar articles
- Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: A phase II, randomized, double-blind trial. (2013-02-20)
- Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. (2012-02-23)
- Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. (2005-08-11)
- Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. (2006-01-05)
- Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. (2005-08-11)
- The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. (2006-06-28)
- Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. (2012-02-22)
- Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (2007-06-25)
- Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. (2002-08-16)
